CytoSite Biopharma is developing a predictive analytics platform that utilizes biomarker profiling to assess patient responses to Immuno-Oncology therapies. This technology enables healthcare providers to tailor treatment plans based on individual patient data, improving therapeutic outcomes and resource allocation.

LimiFlex has developed the Dynamic Sagittal Tether™, a minimally invasive stabilization device designed for patients with grade I degenerative spondylolisthesis and spinal stenosis. This system preserves natural spinal motion while providing necessary stability post-decompression, offering a viable alternative to traditional spinal fusion, which is often invasive and carries significant risks.

Flux develops precision laser cutting and engraving systems that enable users to create intricate designs on various materials, including wood, leather, and glass. Their technology addresses the need for accessible, user-friendly tools that facilitate digital crafting in education, design, and engineering.

InnoVein develops a medical device that provides implants for valve replacement specifically in the femoral vein, utilizing biocompatible materials to ensure compatibility with human tissue. This technology addresses the need for effective treatment options for patients suffering from venous insufficiency and related complications.

Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Third Pole develops devices that generate and deliver electric nitric oxide for therapeutic use in hospitals, outpatient settings, and at home. This technology provides on-demand access to inhaled nitric oxide, which is critical for treating respiratory conditions and improving patient outcomes.

RenovoRx offers a Trans-Arterial Micro-Perfusion (TAMP™) therapy platform that delivers oncology agents directly to solid tumors via the peripheral vascular system. This targeted approach, utilizing the FDA-cleared RenovoCath® device, aims to increase drug concentration at the tumor site while potentially reducing systemic toxicities.

URO-1, Inc. develops surgical devices for office-based urology and urogynecology, including the SUREcore biopsy needle and coreCARE specimen retrieval system, which enhance tissue quality and minimize fragmentation during prostate biopsies and overactive bladder treatments. These innovations address inadequate biopsy samples that lead to diagnostic delays and increased healthcare costs, providing healthcare providers with effective tools to improve clinical outcomes.